dc.contributor.author |
Blom, Dirk J.
|
|
dc.contributor.author |
Breedt, Johannes
|
|
dc.contributor.author |
Burgess, Lesley J.
|
|
dc.contributor.author |
Ebrahim, Iftikhar O.
|
|
dc.contributor.author |
Soma, Prashilla
|
|
dc.contributor.author |
Van der Walt, Eugene
|
|
dc.contributor.author |
Naidoo, Poobalan
|
|
dc.contributor.author |
Van Tonder, Alet
|
|
dc.contributor.author |
Raal, Frederick J.
|
|
dc.date.accessioned |
2020-01-29T10:35:52Z |
|
dc.date.available |
2020-01-29T10:35:52Z |
|
dc.date.issued |
2019-09-21 |
|
dc.description.abstract |
BACKGROUND : Alirocumab reduces low-density lipoprotein
cholesterol (LDL-C) levels by up to 61%. The ODYSSEY
Open-Label Extension study investigated the effect of
alirocumab in patients with heterozygous familial hypercholesterolaemia
(HeFH) over 144 weeks.
METHODS : Eligible patients with HeFH had completed an
earlier double-blind, randomised, placebo-controlled parent
study. Patients were initiated on 75 mg alirocumab Q2W
subcutaneous (SC) unless baseline LDL-C was > 8.9 mmol/l,
in which case they received 150 mg alirocumab Q2W. Dose
titration to 150 mg Q2W was at the investigator’s discretion.
RESULTS : The study enrolled 167 patients and the parent study
mean (± SD) baseline LDL-C level was 3.65 ± 1.9 mmol/l.
Mean LDL-C level was reduced by 48.7% at week 144; mean
on-treatment LDL-C was 2.30 ± 1.24 mmol/l. Eight patients
reported injection-site reactions, with one treatment discontinuation.
Treatment emergent anti-drug antibodies were
identified in five patients but these did not affect the efficacy.
CONCLUSION : Alirocumab effectively and safely reduced LDL-C
in these patients. |
en_ZA |
dc.description.department |
Physiology |
en_ZA |
dc.description.librarian |
hj2020 |
en_ZA |
dc.description.uri |
http://www.cvja.co.za |
en_ZA |
dc.identifier.citation |
Blom, D.J., Breedt, J., Burgess, L.J. et al. 2019, 'Long-term safety and efficacy of alirocumab in
South African patients with heterozygous familial
hypercholesterolaemia : the ODYSSEY open-label extension study', Cardiovascular Journal of Africa, vol. 30, no. 5, pp. 279-284. |
en_ZA |
dc.identifier.issn |
1995-1892 (print) |
|
dc.identifier.issn |
1680-0745 (online) |
|
dc.identifier.other |
10.5830/CVJA-2019-039 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/73010 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Clinics Cardive |
en_ZA |
dc.rights |
© Clinics Cardive Publishing (Pty) Ltd |
en_ZA |
dc.subject |
Alirocumab |
en_ZA |
dc.subject |
PCSK9 inhibitors |
en_ZA |
dc.subject |
Familial hypercholesterolaemia |
en_ZA |
dc.subject |
LDL-C goal |
en_ZA |
dc.subject |
Lipid-lowering therapy |
en_ZA |
dc.subject |
Cardiovascular risk |
en_ZA |
dc.subject |
Statin |
en_ZA |
dc.subject |
Low-density lipoprotein cholesterol (LDL-C) |
en_ZA |
dc.subject |
Heterozygous familial hypercholesterolaemia (HeFH) |
en_ZA |
dc.title |
Long-term safety and efficacy of alirocumab in South African patients with heterozygous familial hypercholesterolaemia : the ODYSSEY open-label extension study |
en_ZA |
dc.type |
Article |
en_ZA |